TL;DR: On 9 Nov 2026 FDA ordered NAION warnings on all GLP-1 RA labels (6.4 vs 3.8 per 100k patient-years). Investigational retatrutide isn't covered.
FDA Orders a Class-Wide NAION Warning on GLP-1 Labels: What the 9 November 2026 Action Says
What Did FDA Announce on 9 November 2026?
On Monday 9 November 2026, the US Food and Drug Administration published a Drug Safety Communication requiring the application holders for every approved GLP-1 receptor agonist (GLP-1 RA) to add information about a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION) to the Warnings and Precautions section of their prescribing information.[1] NAION is a rare condition in which reduced blood flow to the optic nerve causes sudden injury to it; its underlying cause is not well understood.[4]
This is a labelling action, not a restriction on approved indications and not a withdrawal. FDA frames the absolute risk as low and describes a potential increased risk rather than an established causal effect.[1][2] The communication also contains advice for prescribers and patients; we do not reproduce clinical advice here, and readers should consult the FDA page directly.
Why it matters for the literature: until now, NAION questions around this drug class were argued mainly from observational cohorts and litigation. FDA’s action rests on a pooled analysis of randomised trials, which is a different and stronger kind of evidence, even though the event count is small.
What Did FDA’s 126-Trial Meta-Analysis Find?
Because individual trials recorded few or no NAION cases, FDA pooled 126 randomised controlled trials enrolling more than 134,000 participants.[2] Across them it identified 15 probable NAION events: 10 in GLP-1 RA arms and 5 in placebo or active-comparator arms.[1][3]
| Measure (FDA pooled RCT analysis) | GLP-1 RA arms | Comparator arms |
|---|---|---|
| Probable NAION events | 10 | 5 |
| Estimated incidence (per 100,000 patient-years) | 6.4 | 3.8 |
| Mechanism identified in animal data | None identified by FDA’s review | |
Two things are worth noting for anyone reading the numbers. First, the absolute difference between arms is roughly 2.6 events per 100,000 patient-years (our arithmetic from FDA’s published rates), and press coverage translated the treated-arm rate as about 6 in every 100,000 people over a year of exposure.[4] Second, the whole estimate rests on 15 events. With counts that small, the uncertainty around any relative-risk figure is wide, and a handful of reclassified cases could move it noticeably. FDA has said its review of animal data did not identify a mechanism by which GLP-1 RAs could raise NAION risk.[1]
How Did the NAION Question Reach This Point?
FDA says its review began after a July 2024 retrospective cohort study in JAMA Ophthalmology from a single neuro-ophthalmology centre, which reported hazard ratios of 4.28 for semaglutide users with type 2 diabetes and 7.64 for those prescribed it for overweight or obesity.[5] FDA identified several limitations in that study but judged that further assessment was warranted.[2]
In June 2025, the European Medicines Agency’s safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide medicines, potentially affecting up to 1 in 10,000 users, and recommended updating EU product information.[6] Later observational work, including a July 2026 Annals of Internal Medicine target-trial emulation, reported absolute risks below 1 in 1,000 over 18 months, with a modestly higher rate in GLP-1 RA starters; we covered that paper and the related lawsuits in our October guide to what the NAION evidence does and does not show.[7]
Which Products Does the Warning Cover?
According to FDA and trade-press summaries, the requirement extends to exenatide; liraglutide (Victoza, Saxenda) and liraglutide/insulin degludec (Xultophy); dulaglutide (Trulicity); lixisenatide/insulin glargine (Soliqua); semaglutide (Ozempic, Rybelsus, Wegovy); tirzepatide (Mounjaro, Zepbound); and orforglipron (Foundayo), the oral small-molecule GLP-1 RA approved in 2026.[1][3] Including tirzepatide, a dual GIP/GLP-1 agonist, and a non-peptide oral agent confirms FDA is treating this as a GLP-1 receptor class question rather than a molecule-specific one.
Novo Nordisk responded that available research does not establish that GLP-1 medicines cause NAION.[3] We found no Eli Lilly statement specific to the action in the sources reviewed.
Does the FDA NAION Warning Apply to Retatrutide?
No. The action amends the labels of approved products. Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist in Eli Lilly’s Phase 3 TRIUMPH programme; it has no approved label with the FDA, the MHRA or any other regulator, so there is nothing to amend. Lilly has said it plans to submit retatrutide for US approval in the first quarter of 2027.[8] What safety language any future label might carry would be decided in that review; we do not speculate. Our retatrutide FDA approval timeline tracks the filing milestones.
The class framing does make the question visible for researchers following the molecule. Because retatrutide includes GLP-1 receptor agonism, ophthalmic adverse events in the full TRIUMPH publications are a reasonable thing to look for when those papers appear. Lilly’s public toplines to date have not, to our knowledge, singled out NAION. For a dated view of which retatrutide results are peer-reviewed versus sponsor-reported, see our retatrutide evidence status map.
Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
Does This Change Anything in the UK?
The FDA action applies to US labelling. We found no new MHRA communication issued alongside it in the sources reviewed; UK and EU product information for semaglutide had already been updated following the 2025 PRAC review.[6] Nothing in the action changes the legal position of research reagents supplied for in vitro laboratory work, which are not medicinal products and carry no clinical label. For UK pharmacovigilance context, see our summary of MHRA Yellow Card GLP-1 reporting.
How Should Researchers Read a Class Labelling Action?
A Warnings and Precautions update signals that a regulator considers a risk plausible enough to communicate, not that causation is proven. Read the denominator (patient-years), the event count, and the comparator before the headline. Note which products are named, since a class-wide action is a statement about a receptor pharmacology, not about any single molecule’s data. And keep three categories separate: licensed medicines under post-marketing surveillance, investigational drugs in trials, and research reagents with batch documentation. Individuals with questions about a prescribed medicine should speak to their prescriber; this guide is written for laboratory researchers following the regulatory literature.
References
- U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication, 9 November 2026. fda.gov
- Pharmacy Times. FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk. November 2026. pharmacytimes.com
- BioSpace. FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease. November 2026. biospace.com · see also ophthalmologytimes.com
- CNBC. FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound. 10 November 2026. cnbc.com
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology, published online 3 July 2024. doi.org
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 2–5 June 2025 (semaglutide and NAION). ema.europa.eu
- Rutgers-led study of GLP-1 receptor agonists and ischaemic optic neuropathy. Annals of Internal Medicine, July 2026, DOI 10.7326/ANNALS-25-00860. doi.org
- Eli Lilly and Company. Lilly’s triple agonist retatrutide successful in two additional phase 3 obesity trials. Press release, 23 July 2026 (states planned US submission in Q1 2027). biospace.com
Frequently Asked Questions
What did FDA announce about GLP-1 drugs and NAION on 9 November 2026?
FDA issued a Drug Safety Communication requiring holders of every approved GLP-1 receptor agonist application to add information on a potential increased risk of NAION, a rare optic-nerve condition, to the Warnings and Precautions section of their labels.
What data did FDA base the NAION label change on?
FDA pooled 126 randomised controlled trials with more than 134,000 participants. It identified 15 probable NAION events, 10 in GLP-1 RA arms and 5 in comparator arms, giving estimated rates of 6.4 versus 3.8 events per 100,000 patient-years.
Did FDA conclude that GLP-1 drugs cause NAION?
No. FDA describes a potential increased risk and says its review of animal data did not identify a mechanism. Novo Nordisk has said the research does not establish causation. The absolute rates in both arms are very low and rest on 15 events.
Does the FDA NAION warning apply to retatrutide?
No. The action covers approved GLP-1 RA products such as semaglutide, tirzepatide and orforglipron. Retatrutide is an investigational triple agonist in Eli Lilly's Phase 3 programme with no approved label anywhere, so there is no label to amend.
Is Velox Peptides' retatrutide a medicine?
No. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent for qualified laboratory use. It is not a medicine, is not approved by any regulator, and is not for human or veterinary use.